These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28786280)

  • 1. [THE INPUT OF MEASURING INFLIXIMAB LEVELS AND LEVELS OF ANTIBODIES TO INFLIXIMAB IN THE MANAGEMENT OF PATIENTS WITH RHEUMATIC DISEASES].
    Braun-Moscovici Y; Dagan A; Toledano K; Markovits D; Saffouri A; Beshara-Garzoz R; Naffaa ME; Rozin A; Nahir MA; Balbir-Gurman A
    Harefuah; 2017 Jul; 156(7):427-430. PubMed ID: 28786280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
    Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
    Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
    Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
    Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of low level infliximab in the absence of anti-infliximab antibodies.
    Ungar B; Anafy A; Yanai H; Ron Y; Yavzori M; Picard O; Fudim E; Loebstein R; Kopylov U; Chowers Y; Dotan I; Eliakim R; Ben-Horin S
    World J Gastroenterol; 2015 Feb; 21(6):1907-14. PubMed ID: 25684959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
    Steenholdt C; Al-khalaf M; Brynskov J; Bendtzen K; Thomsen OØ; Ainsworth MA
    Inflamm Bowel Dis; 2012 Dec; 18(12):2209-17. PubMed ID: 22344964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.
    Edlund H; Steenholdt C; Ainsworth MA; Goebgen E; Brynskov J; Thomsen OØ; Huisinga W; Kloft C
    AAPS J; 2017 Jan; 19(1):223-233. PubMed ID: 27739011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients.
    Finckh A; Dudler J; Wermelinger F; Ciurea A; Kyburz D; Gabay C; Bas S;
    Joint Bone Spine; 2010 Jul; 77(4):313-8. PubMed ID: 20471890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
    Steenholdt C; Ainsworth MA; Tovey M; Klausen TW; Thomsen OO; Brynskov J; Bendtzen K
    Ther Drug Monit; 2013 Aug; 35(4):530-8. PubMed ID: 23765033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
    Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
    Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of two kits of anti-infliximab antibodies plasmatic measurement].
    Charfi R; Mahmoud I; Ben Salem F; Moalla M; Bouden S; Sfar I; Saïdane O; Klouz A; Daghfous R; Gorgi Y; Abdelmoula L; Trabelsi S
    Ann Biol Clin (Paris); 2019 Aug; 77(4):453-458. PubMed ID: 31418707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
    Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
    Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
    Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
    Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
    Siljehult F; Ärlestig L; Eriksson C; Rantapää-Dahlqvist S
    Scand J Rheumatol; 2018 Sep; 47(5):345-350. PubMed ID: 29701536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.
    van Schaik T; Maljaars JP; Roopram RK; Verwey MH; Ipenburg N; Hardwick JC; Veenendaal RA; van der Meulen-de Jong AE
    Inflamm Bowel Dis; 2014 Dec; 20(12):2292-8. PubMed ID: 25230167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
    Liefferinckx C; Minsart C; Toubeau JF; Cremer A; Amininejad L; Quertinmont E; Devière J; Gils A; van Gossum A; Franchimont D
    Inflamm Bowel Dis; 2017 Aug; 23(8):1371-1381. PubMed ID: 28498153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.